STAT

SEPTEMBER 23, 2022

Market share is often held up as the most relevant metric for the success of a biosimilar class. I believe there are other metrics, like cost savings or signs of greater patient access, that should also be used to define biosimilars’ successes or failures. the first biosimilar was launched in September 2015. In the U.S.,

Biosimilars 237

Biosimilars Diabetes Drug Pricing 237

STAT

JULY 15, 2024

Novo said it has given patients enough time to switch to other options, but is unaware of plans for drugmakers to produce a biosimilar version of the insulin, although Novo would not assert any patent against such a version.

Drug Pricing 237

Drug Pricing Biosimilars Diabetes 237

pharmaphorum

JANUARY 28, 2021

It has been five years since the first biosimilar launched in United States market—marking the first steps in expanding access to innovative biologic-based treatments that help patients manage and treat difficult illnesses such as cancer, rheumatoid arthritis, and other life-altering diseases. million patients.

Biosimilars 119

Biosimilars Insurance Coverage and Processing Drug Pricing Diabetes 119

STAT

MARCH 15, 2024

Thanks to the rising use of various blockbuster drugs, but particularly the so-called GLP-1 medications for treating obesity and diabetes, the outlook for earnings for the pharmaceutical industry is positive over the next 12 to 18 months , according to Moody’s Investor Services. Continue to STAT+ to read the full story…

Drug Pricing 225

Drug Pricing Biosimilars Diabetes 225

Express Pharma

SEPTEMBER 6, 2023

According to the World Health Organisation (WHO), an estimated two billion people across the world do not have access to essential medicines for life threatening diseases like cancer, AIDS and even autoimmune diseases like Type 1 diabetes. The post Is India capable of ensuring equitable access to biopharmaceuticals?

Insurance Coverage and Processing 59

Insurance Coverage and Processing Biosimilars Generic Medicine Drug Pricing 59

Pharmaceutical Technology

DECEMBER 20, 2022

The growing competition from generic drugs presents challenges for the top 20 players placing pressure on drug prices. Although AbbVie’s Humira (adalimumab) is set to face biosimilar competition next year, the blockbuster drug reported strong US sales of $4.96

Vaccines 52

Vaccines Drug Pricing Diabetes Biosimilars 52

pharmaphorum

APRIL 13, 2022

The treatment has been around for over a century but insulin has still become the centre of the ongoing discussion over pricing of pharmaceutical products. Ben Hargreaves looks at why insulin’s price is so controversial and whether this could be set to change. In the US, approximately 37.3 In the US, approximately 37.3

Drug Pricing 130

Drug Pricing Diabetes Biosimilars 130

STAT

MARCH 6, 2023

The company was about to run into a Medicaid penalty for hiking the price of its drugs faster than the rate of inflation. Now that it plans to lower the list price of the insulin Humalog 70%, it won’t trigger that penalty. Lilly also is lowering the price of Lispro, a biosimilar of Humalog, to $25 a vial.

Biosimilars 246

Biosimilars Drug Pricing Diabetes 246

Putting Patients First Blog

JANUARY 27, 2025

The NHC recognizes that Medicare already covers AOMs for patients who are overweight and have comorbid conditions such as diabetes or cardiovascular disease. To further strengthen these efforts, the NHC recommends that CMS adopt additional measures to ensure broad access to generics, biosimilars, and other cost-effective treatments.

Insurance Coverage and Processing 40

Insurance Coverage and Processing Biosimilars Communication Department of Veterans Affairs 40

pharmaphorum

JANUARY 13, 2023

.” He added that people from low-income households and some racial and ethnic groups are disproportionately impacted by the practices, including Hispanic and Black people, who are much more likely to be diagnosed with diabetes than non-Hispanic white people – and much more likely to die as a result of complications.

Diabetes 105

Diabetes Drug Pricing Biosimilars 105

pharmaphorum

MAY 13, 2022

It has filed a lawsuit that accuses the drugmakers and pharmacy benefit managers Express Scripts, Caremark and OptumRx of conspiring to manipulate and inflate insulin prices in the state, inflating their profits and making the drugs unaffordable for many diabetics.

Diabetes 59

Diabetes Biosimilars Drug Pricing 59

pharmaphorum

MARCH 23, 2022

If passed, the Affordable Insulin Now Act would apply the cap across both private health insurance and Medicare plans, and according to Schumer would cut the cost of a 30-day supply of insulin for people with diabetes from a current range of $200 to $600 per person. Some companies are already taking steps to provide lower-cost insulin.

Diabetes 75

Diabetes Biosimilars Drug Pricing 75

Safe Biologics

APRIL 10, 2023

CMS Releases Guidance Memo on Medicare Drug Price Negotiation; Allows Only 30 Days to Comment On March 15, 2023, the Centers for Medicare and Medicaid (CMS) released an initial Guidance Memo regarding implementation of its Medicare Drug Price Negotiation Program, authorized by the Inflation Reduction Act (IRA) signed into law August 16, 2022.

Biosimilars 130

Biosimilars Drug Pricing Diabetes Labelling 130

pharmaphorum

JUNE 18, 2025

Skip to main content Wednesday 18 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views (..)

Diabetes 88

Diabetes Pharmaceutical Companies Pharmaceutical Companies Immunity 88